No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
01877 JUNSHI BIO
- 12.400
- -0.200-1.59%
Trading May 23 10:59 CST
12.22BMarket Cap-5481P/E (TTM)
12.820High12.240Low256.59KVolume12.820Open12.600Pre Close3.20MTurnover0.12%Turnover RatioLossP/E (Static)985.69MShares27.35052wk High1.61P/B2.72BFloat Cap9.17052wk Low--Dividend TTM219.30MShs Float97.150Historical High--Dividend LFY4.60%Amplitude9.170Historical Low12.490Avg Price200Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Institutions Profited After Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Market Cap Rose HK$1.6b Last Week but Individual Investors Profited the Most
Key Insights Significant control over Shanghai Junshi Biosciences by individual investors implies that the general public has more power to influence management and governance-related decisions The
Junshi Biotech (688180.SH): A total of 781,500 shares have been repurchased
Gelonghui, April 30, 丨 Junshi Biotech (688180.SH) announced that as of April 30, 2024, the company had repurchased 781,486 shares through centralized bidding transactions, accounting for 0.0793% of the company's total share capital. The highest repurchase transaction price was RMB 41.69 per share, the lowest price was RMB 29.21 yuan/share, and the total amount of capital paid was RMB 29,883,225.58 (excluding transaction fees such as stamp duty and transaction fees).
Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 6% in the afternoon, Q1 revenue increased 49.24% year-on-year, and losses narrowed by 47.92%
The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 6% in the afternoon. As of press release, it had risen 4.24% to HK$11.3, with a turnover of HK$14.146,600. According to the news, Junshi Biotech announced its results for the first quarter of 2024, with operating income of about 381 million yuan, an increase of 49.24%; net loss attributable to shareholders of listed companies was about 283 million yuan, a year-on-year narrowing of 47.92%; and a basic loss of 0.29 yuan per share. During the reporting period, the increase in the company's revenue was mainly due to the increase in sales revenue of commercial drugs. Among them, the core product, treprilizumab injection (
君實生物：海外監管公告 - 上海君實生物醫藥科技股份有限公司2024年第一季度報告
Junshi Biotech (688180.SH): Net loss of 283 million yuan in the first quarter
Gelonghui, April 29丨Junshi Biotech (688180.SH) released its first quarter report. Operating revenue was 380 million yuan, up 49.24% year on year, net loss of 283 million yuan, net loss of 307 million yuan after deducting non-net loss of 307 million yuan, and basic earnings per share.
君實生物：2023年度報告
Comments
The company's weak revenue trend, unprofitability, and rapid decline in share price reflect poor fundamentals. Last year's performance indicates unresolved challenges, worse than the annualized loss of 9% over the last half decade.
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83% 1
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
Despite Shanghai Junshi Biosciences' weak revenue growth, its P/S ratio aligns with industry peers, indicating investors may be overlooking limited growth expectations and paying a premium. However, this could risk investments as the weak revenue outlook may eventually impact share prices.
Shanghai Junshi Biosciences carries rising debt yet has surplus liquid assets, offsetting risk. Despite having net cash, being a loss-maker might impact its financial health. Be cautious of investing until positive cash flow is seen.
Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg